Cure My Disease

Don't miss your cure!

Log in / Sign up

← Back to home

Eyepoint Pharmaceuticals, Inc.

Clinical trials sponsored by Eyepoint Pharmaceuticals, Inc., explained in plain language.

EyePoint Pharmaceuticals, Inc. EYPT NASDAQ

Develops ophthalmic therapies for eye diseases.

Trade on eToro (ad)

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Trials to join now! 2 Not yet finished but already full! 2 Completed 1

New eye injection could mean fewer doctor visits for wet AMD patients

Disease control Completed

This phase 2 trial tested a new drug called EYP-1901, given as an eye injection, for people with wet age-related macular degeneration (AMD). The goal was to see if it works as well as the standard treatment, aflibercept (Eylea), but with fewer injections. 161 participants receive…

Phase: PHASE2 • Sponsor: EyePoint Pharmaceuticals, Inc. • Aim: Disease control

Last updated Jun 27, 2026 07:54 UTC